TKS-1225

N/A

Report date: 2022/04/14 10:37:38
NME

Base Information

Drug NameTKS-1225
Drug Alias Nameoxyntomodulin analogues (Pfizer)TKS-1225
ClassificationNatural product/ExtractSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptor
Therapy Area/IndicationsObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsObesity

Other Information

ATC CodeN/A
Related LinksN/A